<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871401</url>
  </required_header>
  <id_info>
    <org_study_id>160693</org_study_id>
    <nct_id>NCT02871401</nct_id>
  </id_info>
  <brief_title>A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
  <official_title>A Phase One-B (1B) Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will conduct a single-center, prospective, randomized, placebo-controlled,
      double-blind pilot study of anti-herpesvirus therapy in patients with idiopathic pulmonary
      fibrosis (IPF). Patients with mild, moderate or severe IPF with serologic evidence of current
      or past Epstein-Barr Virus (EBV) or cytomegalovirus (CMV) infection. Randomization will be to
      pirfenidone plus placebo or pirfenidone plus valganciclovir. Thirty subjects will be enrolled
      and randomized to treatment with pirfenidone plus valganciclovir (20 subjects) or pirfenidone
      plus placebo (10 subjects) for 12 weeks. The primary outcome will be safety and tolerability
      will be determined by type, frequency and duration of adverse events (AEs) and serious
      adverse events (SAEs) after 12 weeks of study drug treatment. All study subjects will be
      offered bronchoscopy with bronchoalveolar lavage (BAL) at study initiation and upon
      completion of treatment (12 weeks). Subjects will then be followed up at routine clinic
      visits at 6, 9 and 12 months for data collection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Rate of discontinuation of study drug due to adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events - Number</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number reported adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events - Frequency</measure>
    <time_frame>12 weeks</time_frame>
    <description>Frequency of reported adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events - Severity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Severity of reported adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EBV viral load</measure>
    <time_frame>Baseline vs. 12 weeks</time_frame>
    <description>EBV viral load in BAL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CMV viral load</measure>
    <time_frame>Baseline vs. 12 weeks</time_frame>
    <description>CMV viral load in BAL</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Programmed Death Receptor 1 (PD1) + T cells in peripheral blood</measure>
    <time_frame>Baseline vs. 12 weeks</time_frame>
    <description>Proportion of PD1 +, cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) cells in peripheral blood</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Programmed Death Receptor 1 (PD1) + T cells in peripheral blood</measure>
    <time_frame>Baseline vs. 1 year</time_frame>
    <description>Proportion of PD1 +, cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) cells in peripheral blood</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in PD1+ T cells in BAL</measure>
    <time_frame>Baseline vs. 12 weeks</time_frame>
    <description>Proportion of PD-1 + CD4+ and CD8+ cells in BAL fluid</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in PD1+ T cells in BAL</measure>
    <time_frame>Baseline vs. 1 year</time_frame>
    <description>Proportion of PD-1+ CD4+ and CD8+ cells in BAL fluid</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in T-cell proliferation in peripheral blood</measure>
    <time_frame>Baseline vs. 12 weeks</time_frame>
    <description>Proportion of proliferating CD4+, CD8+ cells from peripheral blood</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in T-cell proliferation in peripheral blood</measure>
    <time_frame>Baseline vs. 1 year</time_frame>
    <description>Proportion of proliferating CD4+, CD8+ cells from peripheral blood</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in T-cell proliferation in BAL</measure>
    <time_frame>Baseline vs. 12 weeks</time_frame>
    <description>Proportion of proliferating CD4+, CD8+ T cells from BAL fluid</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in T-cell proliferation in BAL</measure>
    <time_frame>Baseline vs. 1 year</time_frame>
    <description>Proportion of proliferating CD4+, CD8+ T cells from BAL fluid</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in T-cell cytokine production from peripheral blood</measure>
    <time_frame>Baseline vs. 12 weeks</time_frame>
    <description>EBV/CMV stimulated cytokine production from CD4+, CD8+ T cells from BAL fluid</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in T-cell cytokine production from peripheral blood</measure>
    <time_frame>Baseline vs. 1 year</time_frame>
    <description>EBV/CMV stimulated cytokine production from CD4+, CD8+ T cells from BAL fluid</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in T-cell cytokine production from BAL</measure>
    <time_frame>Baseline vs. 12 weeks</time_frame>
    <description>EBV/CMV stimulated cytokine production from CD4+, CD8+ T cells from peripheral blood</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in T-cell cytokine production from BAL</measure>
    <time_frame>Baseline vs. 1 year</time_frame>
    <description>EBV/CMV stimulated cytokine production from CD4+, CD8+ T cells from peripheral blood</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in forced vital capacity (FVC)</measure>
    <time_frame>Baseline vs. 12 weeks, 1 year</time_frame>
    <description>Percent change in FVC compared to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Oxygen requirement</measure>
    <time_frame>Baseline vs. 12 weeks</time_frame>
    <description>Resting O2 flow (liters per minute)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in 6 Minute Walk Test</measure>
    <time_frame>Baseline vs. 12 weeks</time_frame>
    <description>Distance walked</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute exacerbations</measure>
    <time_frame>1 year</time_frame>
    <description>Acute exacerbation of IPF</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 weeks</time_frame>
    <description>Time to 10% FVC decline, respiratory hospitalization, death or lung transplant</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time to 10% FVC decline, respiratory hospitalization, death or lung transplant</description>
  </other_outcome>
  <other_outcome>
    <measure>Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time to death or lung transplant</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Valganciclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valganciclovir 450 mg, 2 pills by mouth one time per day x 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 2 pills by mouth one time per day x 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.</description>
    <arm_group_label>Valganciclovir</arm_group_label>
    <other_name>Valcyte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age &gt;21 and &lt;80 years

          2. ability to provided informed consent

          3. diagnosis of probable or definite IPF according to American Thoracic Society (ATS)
             criteria

          4. tolerance of full-dose (2403 mg/day) pirfenidone

          5. Positive serology for EBV or CMV

        Exclusion Criteria:

          1. FVC &lt; 40% predicted

          2. Diffusing capacity for carbon monoxide (DLCO) &lt; 35% predicted (Crapo)

          3. Forced expiratory volume (FEV)1/FVC &lt;0.7

          4. Significant centrilobular emphysema (&gt;40% by HRCT)

          5. Active tobacco use (cigarette or cigar smoking)

          6. Resting oxygen saturation (SpO2) on room air &lt;89%

          7. Listed for lung transplantation defined as being assigned a lung allocation score

          8. environmental exposure (occupational, environmental, drug, etc.) felt by the principal
             investigator (PI) to be the etiology of the interstitial disease

          9. diagnosis of collagen-vascular conditions (according to the published American College
             of Rheumatology criteria)

         10. history of unstable or deteriorating cardiac disease

         11. acute coronary syndrome, coronary artery bypass, or angioplasty within 3 months of
             screening

         12. uncontrolled arrhythmia

         13. uncontrolled hypertension

         14. known HIV or hepatitis C

         15. known cirrhosis or chronic active hepatitis

         16. active substance or alcohol abuse

         17. pregnancy or lactation

         18. Women of childbearing potential who are not using a medically approved means of
             contraception. Subjects will be considered of childbearing potential if they are not
             surgically sterile or have not been postmenopausal for at least 2 years [any subject
             who is postmenopausal for &lt; 2 years will be required to have a follicle-stimulating
             hormone (FSH) level to assess her potential to become pregnant

         19. clinically relevant lab abnormalities (obtained within 30 days before enrollment),
             including:

               1. creatinine &gt; 2 x upper limit of normal (ULN)

               2. hematology outside of specified limits: white blood cells (WBCs) &lt; 3,500/mm3;
                  hematocrit &lt; 25% or &gt; 59%; platelets &lt; 100,000/mm3;

               3. total bilirubin &gt; 2 x ULN

               4. Aspartate (AST) or alanine aminotransferases (ALT)/ serum glutamic-oxaloacetic;
                  transaminase (SGOT), or serum glutamic pyruvic transaminase (SGPT) &gt; 2.0 x ULN

               5. alkaline phosphatase &gt; 3 x ULN

               6. albumin &lt; 3.0 mg/dL at screening

         20. known hypersensitivity to study medication

         21. any condition that, in the judgment of the PI, might cause participation in this study
             to be detrimental to the subject or that the PI deems makes the subject a poor
             candidate

         22. any therapy with immunosuppressants such as prednisone, azathioprine, or mycophenolate
             currently or anticipated to be needed during the study period (subjects on these drugs
             prior to the study will require a 30-day washout period before randomization)

         23. participation in another IPF clinical treatment trial during the study period (if
             completing another IPF clinical treatment trial, then a 30-day washout period is
             required before randomization)

         24. requirement for chronic suppressive therapy with valacyclovir for recurrent herpes
             virus infection

         25. History of myelodysplasia, aplastic anemia, refractory anemia, or multiple myeloma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan A Kropski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendi Mason, NP</last_name>
    <phone>615-343-7068</phone>
    <email>wendi.mason@vanderbilt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan kropski, MD</last_name>
    <phone>615-875-7935</phone>
    <email>jon.kropski@vanderbilt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendi R Mason, NP</last_name>
      <phone>615-343-7068</phone>
      <email>wendi.mason@vanderbilt.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Jonathan Kropski</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>IPF</keyword>
  <keyword>Herpesvirus</keyword>
  <keyword>Valganciclovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

